Brain metastases.
نویسندگان
چکیده
Brain metastases are an increasingly common complication in patients with systemic cancer. The optimal treatment for each patient depends on careful evaluation of several factors: the location, size, and number of brain metastases; the patient's age, general condition, and neurologic status; and the extent of systemic cancer to name a few. For patients with a single brain metastasis and limited systemic disease, the standard treatment is surgical resection followed by whole brain radiation therapy. In patients with a small, single metastasis, stereotactic radiosurgery is probably comparable to surgery. Patients with several metastases (up to three) and controlled systemic disease can be treated with whole-brain radiation and stereotactic radiosurgery. Patients with multiple metastases (more than three) are generally treated with whole-brain radiation alone. Radiosurgery is effective in treating patients with a limited number of recurrent brain metastases and stable systemic diseases. Surgery may have a role in patients with a large symptomatic recurrent lesion producing mass effect. Reirradiation and chemotherapy may have a limited role in patients with multiple recurrent metastases.
منابع مشابه
Dosimetric comparison of two different whole brain radiotherapy techniques in patients with brain metastases: How to decrease lens dose?
Background: Palliative whole brain radiotherapy (WBRT) has been the standard treatment for brain metastases. Ionizing radiation is known to be one of the most potent cataractogenic agents. We aimed to evaluate two different radiotherapy techniques with respect to the doses received by the organs at risk (OAR) in patients with brain metastasis who undergone WBRT. Materials and Methods: Ten conse...
متن کاملPapillary thyroid cancer with metastases to brain, lung and kidney: A case of dosimetry proven privilege of surgical resection of organ metastases
A 45-year-old woman presented with a headache and visual complaints. Brain MRI revealed a large mass in the right occipital cortex. The tumor was surgically removed and pathological examination showed papillary carcinoma originating from thyroid gland. She had a history of thyroid surgery 27 years ago indicating papillary thyroid cancer with central neck lymph node involvement followed by no ad...
متن کاملبررسی بقا بر اساس سیستم نمرهبندی GPA در مبتلایان به متاستازهای مغزی درمان شده با رادیوسرجری گامانایف
Abstract Background: This study was done to define the role of Graded Prognostic Assessment (GPA) score for predicting overall survival in patients diagnosed with brain metastases undergoing Gamma-knife radiosurgery. Materials and methods: Patients diagnosed with brain metastases who were candidates for Gamma-knife radiosurgery entered this cross sectional study between 2003 and 2011. Clin...
متن کاملبکارگیری مدل مخاطرات متناسب کاکس در شناسایی عوامل موثر بر بقای بیماران مبتلا به متاستاز مغزی
Abstract Background : The aim of this study is to determine of risk factors in patients with brain metastases, and prognostic factors affecting survival of patients by using the Cox proportional hazards model. Methods : This descriptive - analytic retrospective study was performed on 197 patients with brain metastases who Referred to Shahid Ramezanzadeh Radiation Center, Yazd, Iran. Several ris...
متن کاملClinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases
Brain metastases from non-medullary thyroid carcinoma (NMTC) are rare, with a reported frequency of ~1%, and patient survival time is <1 year after diagnosis. The optimal management of brain metastases in this setting continues to be debated. The aim of the present study was to evaluate a series of patients with brain metastases from NMTC attending a single tertiary medical center. The electron...
متن کاملClinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
Brain metastasis in non small cell lung cancer (NSCLC) patients is often considered as a terminal stage of advanced disease. Crizotinib is a small-molecule tyrosine kinase inhibitor (TKI) for ALK-rearranged NSCLC patients. Herein, we conducted a retrospective study to explore how Crizotinib affects the control of brain metastases and the overall prognosis in advanced ALK-rearranged NSCLC patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Current treatment options in oncology
دوره 1 5 شماره
صفحات -
تاریخ انتشار 2000